Proteome Sciences (LON:PRM) Stock Price Up 2.5% – Still a Buy?

Proteome Sciences plc (LON:PRM)’s share price shot up 2.5% during mid-day trading on Thursday . The company traded as high as GBX 1.61 and last traded at GBX 1.45. 237,053 shares changed hands during mid-day trading, a decline of 42% from the average session volume of 410,030 shares. The stock had previously closed at GBX 1.42.

Proteome Sciences Stock Performance

The company has a debt-to-equity ratio of -165.46, a current ratio of 0.13 and a quick ratio of 0.37. The stock has a 50-day simple moving average of GBX 1.61 and a 200-day simple moving average of GBX 1.98. The stock has a market cap of £5.26 million, a P/E ratio of -1.33 and a beta of 0.07.

Proteome Sciences (LON:PRM) last released its earnings results on Wednesday, April 15th. The company reported GBX (1.04) earnings per share (EPS) for the quarter. Proteome Sciences had a negative net margin of 81.50% and a positive return on equity of 33.80%. The business had revenue of GBX 376 million during the quarter.

Proteome Sciences Company Profile

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant, provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator, analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids.